The Adjuvant Use Of Calcium Fructoborate And Borax With Etanercept In Patients With Rheumatoid Arthritis: Pilot Study
Notes for this study:
||(mm/H). Mean and SD. Placebo: before 27.2 (6.1), after 24.0 (7.8). Sodium tetraborate: before 28.3 (8.3), after 20.4 (9.2). Calcium fructoborate: before 27.8 (5.6), after 18.8 (4.8).
|Number of Subjects
In a randomized, double-blind, placebo-controlled trial 80 participants with rheumatoid arthritis were allocated to take 220 mg of calcium fructoborate, 55 mg of sodium tetraborate, both containing 6 mg of elemental boron, or placebo for 8 weeks. Participants were all taking etanercept. Tenderness and swollenness of joints, as well as pain on a visual analog scale and evaluator's global assessment (EGA) were reduced more in the boron groups than the placebo group, without statistically significant differences between them.
Erythrocyte sedimention rate, c-reactive protein, IL-1a, and IL-6 were all notably decreased more by boron than placebo.